Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
Clinical trial NCT05131204 · TERMINATED
Trial details
- NCT number
- NCT05131204
- Sponsor
- Regeneron Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-06
- Primary completion
- 2023-07-12
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.